Synapse - Dana Rathkopf

Results (277)

Androgen deprivation therapy drives a distinct immune phenotype in localized prostate cancer

Journal Article

Dallos, M. C.; Obradovic, A. Z.; McCann, P.; Chowdhury, N.; Pratapa, A.; Aggen, D. H.; Gaffney, C.; Autio, K. A.; Virk, R. K.; De Marzo, A. M.; more...
Clinical Cancer Research (2024)

Fulltext@MSK | Save

Apalutamide (APA) plus intermittent versus continuous androgen-deprivation therapy (ADT) in participants (pts) with metastatic castration-sensitive prostate cancer (mCSPC): LIBERTAS phase 3 study design

Meeting Abstract

Azad, A.; Badillo, M. A.; Dong, Q.; Morgans, A. K.; Rathkopf, D. E.; Runcie, K.; Zhang, T.; Pruthi, R.; Bhaumik, A.; Mundle, S.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Post radical prostatectomy (RP) PSA outcomes following 6 versus 18 months of perioperative androgen receptor signaling inhibitors (ARSI) in men with localized high-risk prostate cancer: Results of Part 2 of a randomized phase 2 trial

Meeting Abstract

McKay, R. R.; Xie, W.; Yang, X.; Acosta, A.; Rathkopf, D. E.; Laudone, V. P.; Bubley, G.; Einstein, D. J.; Chang, P. T.; Wagner, A.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Patient-reported health-related quality of life (HRQoL) in the randomized FORMULA-509 trial of salvage radiotherapy and 6 months of GnRH agonist with either bicalutamide or abiraterone acetate plus prednisone (AAP) and apalutamide (Apa) after radical prostatectomy (RP)

Meeting Abstract

Hoffman, K. E.; Nguyen, P. L.; Rathkopf, D. E.; Zurita, A. J.; Spratt, D. E.; Dess, R. T.; Liauw, S. L.; Szmulewitz, R. Z.; Einstein, D. J.; Bubley, G.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Patient-reported outcomes (PRO) in patients (pts) with BRCA1/2-altered metastatic castration-resistant prostate cancer (mCRPC) receiving niraparib (NIRA) with abiraterone acetate and prednisone (AAP): Results from MAGNITUDE study

Meeting Abstract

Rathkopf, D. E.; Roubaud, G.; Chi, K. N.; Efstathiou, E.; Attard, G.; Olmos, D.; Small, E. J.; Saad, M.; Castro, E.; Kim, W.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

First-in-human phase 1 study of CC-94676, a first-in-class androgen receptor (AR) ligand-directed degrader (LDD), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Rathkopf, D. E.; Patel, M. R.; Choudhury, A. D.; Rasco, D. W.; Lakhani, N. J.; Hawley, J. E.; Aparicio, A.; Narayan, V.; Srinivas, S.; Runcie, K.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Microsatellite instability, tumor mutational burden, and response to immune checkpoint blockade in patients with prostate cancer

Journal Article

Lenis, A. T.; Ravichandran, V.; Brown, S.; Alam, S. M.; Katims, A.; Truong, H.; Reisz, P. A.; Vasselman, S.; Nweji, B.; Autio, K. A.; more...
Clinical Cancer Research (2024)

Fulltext@MSK | Save

LIBERTAS: A degendered and transgender-inclusive phase 3 study of apalutamide (APA) plus intermittent vs continuous androgen deprivation therapy (ADT) in participants (pts) with metastatic hormone-sensitive prostate cancer (mHSPC)